Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
Key Highlights: Implications: Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.&nb...
Key Highlights: Implications: Tishtha detonates pricing bombs on Roche’s Tecentriq and MSD’s Opdivo, handing cash-strapped hospitals a lifeline while exploding p...
